Please note most of these publications were published by our predecessor company CellPoint, LLC.

CENTENNIAL, Colo., June 21, 2010

Cell>Point announced today that it has submitted to the US Food and Drug Administration (FDA) an Investigational New Drug (IND) application for a Phase 1b/2 trial of itsĀ 99mTc-EC-G diagnostic in assessing patients with Coronary Artery Disease (CAD).